Literature DB >> 24982398

Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.

Masatsune Shibutani1, Kiyoshi Maeda2, Hisashi Nagahara2, Hiroshi Ohtani2, Katsunobu Sakurai2, Takahiro Toyokawa2, Naoshi Kubo2, Hiroaki Tanaka2, Kazuya Muguruma2, Masaichi Ohira2, Kosei Hirakawa2.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the significance of the combination of the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels as a prognostic indicator and for monitoring for recurrence and metastasis after potentially curative surgery for patients with stage II colorectal cancer. PATIENTS AND METHODS: A total of 238 patients with stage II colorectal cancer who underwent potentially curative surgery were enrolled in the study. A high CEA level was defined as a level exceeding 5 ng/ml and a high CA19-9 level was defined as a level exceeding 37 U/ml.
RESULTS: Out of these 238 patients, 92 (38.7%) patients had high CEA levels, 23 (9.7%) patients had high CA19-9 levels and 15 (6.3%) patients had both high CEA and CA19-9 levels. The disease-free and overall survival rates were significantly worse in patients with both a high CEA level and high CA19-9 level. Tumor marker(s) elevated before the operation tended to be elevated again at the time of relapse.
CONCLUSION: The combination of preoperative CEA and CA19-9 levels was useful for predicting the prognosis and for monitoring recurrence and metastasis after potentially curative surgery in patents with stage II colorectal cancer. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; carbohydrate antigen; carcinoembryonic antigen; prognosis; stage II

Mesh:

Substances:

Year:  2014        PMID: 24982398

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  37 in total

1.  Serum GROβ: a potential tumor-associated biomarker for colorectal cancer.

Authors:  Zhaoxu Zheng; Min Zheng; Jianjun Bi; Qiang Feng; Zhigang Yue; Yanqiu Zhou; Wanning Hu; Haizeng Zhang; Hongjun Gao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  A microfluidic platform with digital readout and ultra-low detection limit for quantitative point-of-care diagnostics.

Authors:  Ying Li; Jie Xuan; Yujun Song; Ping Wang; Lidong Qin
Journal:  Lab Chip       Date:  2015-08-21       Impact factor: 6.799

3.  Predicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data Base.

Authors:  Emmanuel Gabriel; Kristopher Attwood; Pragatheeshwar Thirunavukarasu; Eisar Al-Sukhni; Patrick Boland; Steven Nurkin
Journal:  J Am Coll Surg       Date:  2015-12-23       Impact factor: 6.113

4.  Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Authors:  Yifan Peng; Zhiwei Zhai; Zhongmin Li; Lin Wang; Jin Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer.

Authors:  Ying Li; Jie Xuan; Yujun Song; Wenjin Qi; Bangshun He; Ping Wang; Lidong Qin
Journal:  ACS Nano       Date:  2015-12-28       Impact factor: 15.881

6.  Development of a novel model for predicting survival of patients with spine metastasis from colorectal cancer.

Authors:  Yujie Liu; Minglei Yang; Bo Li; Kehan Xu; Xin Gao; Jialin Li; Haifeng Wei; Quan Huang; Wei Xu; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-01-18       Impact factor: 3.134

7.  Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.

Authors:  Mitsunori Ushigome; Hideaki Shimada; Yasuyuki Miura; Kimihiko Yoshida; Tomonori Kaneko; Takamaru Koda; Yasuo Nagashima; Takayuki Suzuki; Satoru Kagami; Kimihiko Funahashi
Journal:  Int J Clin Oncol       Date:  2019-12-09       Impact factor: 3.402

8.  Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.

Authors:  Jingtao Wang; Xiao Wang; Fudong Yu; Jian Chen; Senlin Zhao; Dongyuan Zhang; Yang Yu; Xisheng Liu; Huamei Tang; Zhihai Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II/III colon cancer.

Authors:  Hironori Mizuno; Hideo Miyake; Hidemasa Nagai; Yuichiro Yoshioka; Koji Shibata; Soichiro Asai; Junichi Takamizawa; Norihiro Yuasa
Journal:  Langenbecks Arch Surg       Date:  2021-06-19       Impact factor: 3.445

10.  A Nomogram for Predicting Multiple Metastases in Metastatic Colorectal Cancer Patients: A Large Population-Based Study.

Authors:  Yuhang Ge; Renshen Xiang; Jun Ren; Wei Song; Wei Lu; Tao Fu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.